BelSU Scientist Comments on Discovery of Protein «That Reverses Brain Ageing»

In an interview on the Slushaem! educational channel, Alexey Deykin discussed the significant findings from American neurobiologists at the University of California, who announced a potential method for reversing brain aging.

The researchers examined how gene activity and protein levels in the hippocampus – an area of the brain closely linked to learning, memory, and emotions – differ between young and old laboratory mice. Among the various indicators studied, only the FTL1 protein showed marked differences. Older mice exhibited higher levels of FTL1, alongside reduced connections between brain cells in the hippocampus and diminished cognitive abilities. Following a series of experiments, the scientists concluded that the FTL1 protein accelerates the aging process and increases the risk of serious neurological disorders, such as Alzheimer’s disease. They suggested that regulating FTL1 could be a promising avenue for preventing and treating these conditions.

Deykin explained, “The researchers found that when the FTL1 protein is reduced, the cognitive abilities of adult mice significantly improve, approaching those of younger mice.”

He elaborated that as individuals age, their bodies weaken, and elderly brains cannot handle the same cognitive load as those at twenty. Over countless generations of evolution, nature has developed a protective mechanism to safeguard older brains from overload.

“Scientists have discovered a natural ‘switch’ that slows down brain function, which can potentially be increased. However, continually ramping up this speed may lead to adverse effects, so it is clearly not a cure-all,” Deykin cautioned.

The geneticist also pointed out that nature has created living organisms in harmony, with all organs and systems designed to function for a similar lifespan. Therefore, he argued that simply extending brain longevity is insufficient; the entire body must be prepared to live longer while maintaining its functions, and medicine is advancing in this direction.

Looking ahead, Deykin believes that the findings from his American colleagues could aid in addressing specific symptoms, such as memory loss. He estimates that a new drug aimed at alleviating age-related changes in the brain may take approximately 15 to 20 years to develop, with clinical trials alone requiring about 10 years. 

“There is a long journey from the first patient administration to a drug being available in pharmacies, which is why we rarely hear about new medications entering the market,” he noted.

Deykin also mentioned that current scientific research identifies twelve different mechanisms of aging, each with corresponding strategies for combating it; thus, FTL1 is not the sole hope for prolonging youth.

To listen to the full episode of the programme, please visit the website.